Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”), announces that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. (“Alkeus”), a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The pending transaction details include upfront considerationof approximately $450 million, consisting of $270 million in cash and $180 million in Tarsus common stock, milestones of up to $350 million upon potential regulatory approval and first commercial sale, and low single digit tiered descending royalties as a percentage of gildeuretinol net sales.
Read the full article: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position //
Source: https://www.globenewswire.com/news-release/2026/08/06/3340125/0/en/tarsus-pharmaceuticals-to-acquire-alkeus-pharmaceuticals-and-advance-eye-care-leadership-position.html?_gl=1*apr02d*_up*MQ..*_ga*MTQ1NzE5MDM5OS4xNzg2MDE1MDM2*_ga_B6167QB2TF*czE3ODYwMTUwMzUkbzEkZzAkdDE3ODYwMTUwMzUkajYwJGwwJGg1NjQ3Njc4NDg.*_ga_ERWPGTJ5X8*czE3ODYwMTUwMzYkbzEkZzAkdDE3ODYwMTUwMzYkajYwJGwwJGgw